Articles

Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial

Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al Eur J Cancer. 2025 Jun 18:223:115489

We assessed the association of BMI and weight changes with outcomes of patients with HER2-positive early BC included in the APHINITY trial. This is an exploratory analysis of APHINITY (NCT01358877), randomized trial testing adjuvant dual vs. single HER2 blockade plus chemotherapy in HER2-positive early BC. Of 4787 ... Read More

12 May, 2026

Trends in Mammography Use Among Women Aged 40 to 74 Years in the US, 2002-2022

Syed Mahfuz Al Hasan, Debbie L Bennett, Adetunji T Toriola. JAMA Netw Open. 2026 Mar 2;9(3):e263529

Objective: To analyze mammography use trends in US women aged 40 to 49 and 50 to 74 years from 2002 to 2022. Among 2,619,292 US women, mammography use showed a downward trend, with nonsignificant biennial changes of -0.54% for ages 40 to 49 years and -0.16% for ages 50 to 74 years from 2002 to 2022. Declines were s... Read More

12 May, 2026

Cost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada

Anna N Wilkinson, James G Mainprize, Martin J Yaffe, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2452821

Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards. Incremental cost-effectiveness ratios for deaths averted, life-years (LYs) gained, and incremental cost-utility ratios for quality-adjusted life-years (QALYs) gained were determ... Read More

12 May, 2026

Screening programmes and breast cancer mortality: an observational study of 194 countries

Syed Mahfuz Al Hasan, Debbie L Bennett, and Adetunji T Toriola. Bull World Health Organ.2025 Aug 1;103(8):470-483

We collected data on breast cancer screening programmes and breast cancer mortality from the World Health Organization's Global Health Observatory, the Global Burden of Diseases 2021 study and the Eurostat database. Between 2015 and 2021, 94 of 194 countries reported having national breast cancer screening program... Read More

12 May, 2026

Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer

Sida Huang, Sarah J Westvold, Pamela R Soulos, et al. JAMA Netw Open. 2025 Apr 1;8(4):e255322

Screening mammography promotes early detection of breast cancer and is associated with reduced breast cancer mortality. Screening history prior to diagnosis may impact stage at diagnosis and breast cancer mortality. Among 13,028 included women, most had at least 1 prior screening (10 094 women [77.5%]) and were age... Read More

12 May, 2026

Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis

Javier David Benitez Fuentes, Eileen Morgan, Alicia de Luna Aguilar et al. JAMA Oncol. 2024 Jan 1;10(1):71-78

Objective: To assess the global distribution of breast cancer stage by country, age group, calendar period, and socioeconomic status using population-based data. Data were available for 2.4 million women with breast cancer from 81 countries. Globally, the proportion of cases with distant metastatic breast cancer at... Read More

12 May, 2026

Trends of Female Breast Cancer Burden in China over 25 Years: A Join Point Regression and Age-Period-Cohort Analysis Based on the GBD (1997-2021)

Yuanyan Tang, Jia Zhu and Zhengren Liu. Cancer Invest. 2025 Sep;43(8):610-622

This study analyzed the trends of BC among Chinese women from 1997 to 2021 to support evidence-based for the prevention, screening and treatment strategies of female BC in China. We extracted data on BC incidence, mortality, prevalence, disability-adjusted life years (DALYs), years lived with disability (YLDs) and... Read More

12 May, 2026

Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status

Shuai Xu, Sara Murtagh, Yunan Han,et al. JAMA Netw Open. 2024 Jan 2;7(1):e2353331

Breast cancer in young women has a less favorable prognosis compared with older women. This cross-sectional study used data from Surveillance, Epidemiology, and End Results 17 registries (2000-2019). Women aged 20 to 49 years with a primary invasive breast cancer were included. Out of 217 815 eligible women, the m... Read More

12 May, 2026

Global patterns and risk factors of breast cancer in women under 35: a population-based study

Dechuang Jiao, Jiujun Zhu, Dandan Wang, et al. Breast. 2026 Mar 23:87:104777

Accurate estimates of the global burden of young breast cancer (YBC) are lacking. In 2021, YBC accounted for substantial global disease burden, with 81,856 new cases, 687,819 prevalent cases, 18,597 deaths, and 1,178,721 DALYs. From 1990 to 2021, global ASIR (AAPC: 1.3%) and ASMR (AAPC: 0.3%) increased significant... Read More

12 May, 2026

The global burden of early-onset cancer in women, 1990-2021: findings from the GBD 2021 with focus on China

Yibei Li, Danqi Huang, Jingyi Liu, et al. J Natl Cancer Cent. 2026 Feb 11;6(2):149-158

Early-onset cancer is a significant public health threat in females, yet comprehensive data on its global burden and temporal trends remain limited. This study analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of female early-onset cancers (ages 15-49 years) from 1990 to 2021, with proje... Read More

12 May, 2026